IBS News

Subscribe to IBS News feed
IBS Patient Community - IBSpatient.org - IBS News
Updated: 38 min ago

Google-It's the 2nd-leading cause of absence from work - MyDaytonDailyNews

Jul 24, 2017
It's the 2nd-leading cause of absence from work MyDaytonDailyNews Irritable bowel syndrome, also known as IBS, is a health issue that affects up to 20 percent of Americans with many chronic symptoms such as intermittent bowel pain, altered bowel habits, gas and bloating. The issues may seem minor to most, but for ... and more » View the full article

Google-Participants sought for Irritable Bowel Syndrome Study - The Irish World Newspaper

Jul 24, 2017
Participants sought for Irritable Bowel Syndrome Study The Irish World Newspaper NUI Galway is seeking over a 1,000 women to participate in an online study on how their personal psychology can influence their Irritable Bowel Syndrome, Crohn's disease or Colitis. The symptoms of both irritable bowel syndrome and inflammatory bowel ... View the full article

Google-Ease IBS symptoms by managing stress - TV3.ie

Jul 24, 2017
TV3.ie Ease IBS symptoms by managing stress TV3.ie Irritable bowel syndrome (IBS) is a common, long-term condition of the digestive system that affects millions of people around the world, including Tyra Banks and Jenny McCarthy. It can cause bouts of stomach cramps, bloating, diarrhoea and/or ... and more » View the full article

Google-Ease IBS symptoms by managing stress - TV3.ie

Jul 24, 2017
TV3.ie Ease IBS symptoms by managing stress TV3.ie Irritable bowel syndrome (IBS) is a common, long-term condition of the digestive system that affects millions of people around the world, including Tyra Banks and Jenny McCarthy. It can cause bouts of stomach cramps, bloating, diarrhoea and/or ... and more » View the full article

Pubmed-Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.

Jul 24, 2017
Related Articles Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol. 2017 Jul 22;: Authors: Whitehead SJ, Ford C, Gama RM, Ali A, McKaig B, Waldron JL, Steed H, Brookes MJ Abstract AIMS: To prospectively evaluate whether between-assay variability of different faecal calprotectin (f-Cp) assays influences diagnostic accuracy for inflammatory bowel disease (IBD) in a cohort of patients with confirmed IBD and irritable bowel syndrome (IBS). To also evaluate the diagnostic accuracy of faecal S100A12 (f-S100A12) against f-Cp in the same patient cohort and assess whether f-S100A12 offers additional diagnostic value. METHODS: F-Cp using four commercially available f-Cp assays, f-S100A12 and blood biomarkers were measured in patients, recruited from the local IBD clinic, who had established IBS or active ulcerative colitis (UC) and Crohn's disease (CD). Diagnostic sensitivities and specificities for each assay and biomarker were calculated and compared. RESULTS: Median f-Cp levels in all assays were significantly higher in UC (347-884 µg/g; n=28) and CD (377-838 µg/g; n=15) compared with IBS (6-27 µg/g; n=17). Sensitivities and specificities at 50 µg/g were 94%-100% and 82%-100%, respectively. Median f-S100A12 levels were significantly higher in UC (81.0 µg/g; IQR 38.3-159.8) and CD (47.2 µg/g; IQR 5.3-108.9) compared with IBS (0.7 µg/g; IQR 0.5-0.8). At 2.8 µg/g, f-S100A12 had a sensitivity of 97% and specificity of 94%. The blood biomarkers demonstrated sensitivities and specificities of 44%-63% and 80%-92%, respectively. CONCLUSIONS: The diagnostic sensitivity of the calprotectin assays was similar despite inter-kit variability in absolute values. There is a need for f-Cp assay standardisation, but in its absence assay-specific cut-off values may optimise their diagnostic performance. F-S100A12 demonstrated comparable sensitivity and specificity to f-Cp and although a research tool at present, may have a future role to play in the diagnosis and management of these patients. PMID: 28735301 [PubMed - as supplied by publisher] View the full article

Google-We reveal the first diet proven to help bowel disorders such as Irritable Bowel Syndrome - Mirror.co.uk

Jul 23, 2017
Mirror.co.uk We reveal the first diet proven to help bowel disorders such as Irritable Bowel Syndrome Mirror.co.uk All of these are sugars in everyday foods but many are poorly absorbed in the small intestine where they hang around fermenting, producing gas and making you bloated. Researchers believe they're responsible for the discomfort and bloating of IBS. View the full article

Google-'It shouldn't be laughed at': Study begins on effect bowel disorders have on women's minds - thejournal.ie

Jul 22, 2017
thejournal.ie 'It shouldn't be laughed at': Study begins on effect bowel disorders have on women's minds thejournal.ie Researchers at the university's School of Psychology are looking for 1,000 women to take part in an online study about how conditions like Irritable Bowel Syndrome (IBS), Crohn's disease or ulcerative colitis affects them. Irritable bowel syndrome is a ... View the full article

Pubmed-SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.

Jul 22, 2017
Related Articles SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada. Gastroenterol Hepatol (N Y). 2017 Feb;13(2 Suppl 1):1-16 Authors: Chey WD Abstract Many nonpharmacologic and pharmacologic therapies are available to manage irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). The American College of Gastroenterology (ACG) regularly publishes reviews on IBS and CIC therapies. The most recent of these reviews was published by the ACG Task Force on the Management of Functional Bowel Disorders in 2014. The key objective of this review was to evaluate the efficacy of therapies for IBS or CIC compared with placebo or no treatment in randomized controlled trials. Evidence-based approaches to managing diarrhea-predominant IBS include dietary measures, such as a diet low in gluten and fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs); loperamide; antispasmodics; peppermint oil; probiotics; tricyclic antidepressants; alosetron; eluxadoline, and rifaximin. Evidence-based approaches to managing constipation-predominant IBS and CIC include fiber, stimulant laxatives, polyethylene glycol, selective serotonin reuptake inhibitors, lubiprostone, and guanylate cyclase agonists. With the growing evidence base for IBS and CIC therapies, it has become increasingly important for clinicians to assess the quality of evidence and understand how to apply it to the care of individual patients. PMID: 28729815 [PubMed] View the full article

Pubmed-Extracellular signal-regulated kinase activation in the spinal cord contributes to visceral hypersensitivity induced by craniofacial injury followed by stress.

Jul 22, 2017
Related Articles Extracellular signal-regulated kinase activation in the spinal cord contributes to visceral hypersensitivity induced by craniofacial injury followed by stress. Neurogastroenterol Motil. 2017 Jul 21;: Authors: Zhao YJ, Li JH, Hu B, Wang Y, Chang XF, Traub RJ, Cao DY Abstract BACKGROUND: We previously developed an animal model to examine mechanisms that underlie the emergence of visceral hypersensitivity modeling pain characteristics of temporomandibular disorder (TMD) patients with comorbid irritable bowel syndrome (IBS). In ovariectomized (OVx) rats with estradiol (E2) replacement, visceral hypersensitivity developed subsequent to masseter muscle inflammation followed by repeated forced swim (FS) stress. The purpose of this study was to investigate whether activation of extracellular signal-regulated kinase (ERK) in the spinal cord contributes to visceral hypersensitivity in this overlapping pain model. METHODS: In OVx with E2 replacement rats masseter muscle inflammation was followed by 3 day FS (comorbid condition). Depression-like behaviors were assessed by sucrose preference and in the elevated plus maze, and visceral sensitivity was measured by the visceromotor response (VMR) to colorectal distention. The protein level of ERK1/2 and phosphorylated ERK1/2 (p-ERK1/2) in the L6-S2 dorsal spinal cord was analyzed by western blot. KEY RESULTS: FS stress decreased sucrose consumption in E2 replaced rats in sucrose preference test. The expression of p-ERK1/2 in the L6-S2 dorsal spinal cord increased significantly in E2 with comorbid rats. Intrathecal injection of mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor PD98059 blocked the visceral hypersensitivity induced by masseter muscle inflammation combined with FS stress. CONCLUSIONS & INFERENCES: These data indicate that ERK1/2 activation contributes to the visceral hypersensitivity evoked by craniofacial inflammation pain combined with stress. The results may provide a new therapeutic avenue for alleviating overlapping pain conditions. PMID: 28730748 [PubMed - as supplied by publisher] View the full article

Pubmed-Dietary fiber in irritable bowel syndrome (Review).

Jul 22, 2017
Dietary fiber in irritable bowel syndrome (Review). Int J Mol Med. 2017 Jul 19;: Authors: El-Salhy M, Ystad SO, Mazzawi T, Gundersen D Abstract Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder. It is widely believed that IBS is caused by a deficient intake of dietary fiber, and most physicians recommend that patients with IBS increase their intake of dietary fiber in order to relieve their symptoms. However, different types of dietary fiber exhibit marked differences in physical and chemical properties, and the associated health benefits are specific for each fiber type. Short-chain soluble and highly fermentable dietary fiber, such as oligosaccharides results in rapid gas production that can cause abdominal pain/discomfort, abdominal bloating/distension and flatulence in patients with IBS. By contrast, long-chain, intermediate viscous, soluble and moderately fermentable dietary fiber, such as psyllium results in a low gas production and the absence of the symptoms related to excessive gas production. The effects of type of fiber have been documented in the management of IBS, and it is known to improve the overall symptoms in patients with IBS. Dietary fiber acts on the gastrointestinal tract through several mechanisms, including increased fecal mass with mechanical stimulation/irritation of the colonic mucosa with increasing secretion and peristalsis, and the actions of fermentation byproducts, particularly short-chain fatty acids, on the intestinal microbiota, immune system and the neuroendocrine system of the gastrointestinal tract. Fiber supplementation, particularly psyllium, is both safe and effective in improving IBS symptoms globally. Dietary fiber also has other health benefits, such as lowering blood cholesterol levels, improving glycemic control and body weight management. PMID: 28731144 [PubMed - as supplied by publisher] View the full article

Pubmed-[Irritable bowel syndrome in medical students from Latin America: an overlooked problem?]

Jul 22, 2017
[Irritable bowel syndrome in medical students from Latin America: an overlooked problem?] Rev Gastroenterol Peru. 2017 Apr-Jun;37(2):190-191 Authors: Novoa-Sandoval P, Pérez-Acuña K, Achata-Espinoza M, Toro-Huamanchumo CJ PMID: 28732004 [PubMed - in process] View the full article

Pubmed-Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.

Jul 22, 2017
Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PLoS One. 2017;12(7):e0181863 Authors: Brun P, Scarpa M, Marchiori C, Sarasin G, Caputi V, Porzionato A, Giron MC, Palù G, Castagliuolo I Abstract BACKGROUND: We evaluated the effect of Saccharomyces boulardii CNCM I-745 on intestinal neuromuscular anomalies in an IBS-type mouse model of gastrointestinal motor dysfunctions elicited by Herpes Simplex Virus type 1 (HSV-1) exposure. METHODS: Mice were inoculated intranasally with HSV-1 (102 PFU) or vehicle at time 0 and 4 weeks later by the intragastric (IG) route (108 PFU). Six weeks after IG inoculum, mice were randomly allocated to receive oral gavage with either S. boulardii (107 CFU/day) or vehicle. After 4 weeks the following were determined: a) intestinal motility using fluorescein-isothiocyanate dextran distribution in the gut, fecal pellet expulsion, stool water content, and distal colonic transit of glass beads; b) integrity of the enteric nervous system (ENS) by immunohistochemistry on ileal whole-mount preparations and western blot of protein lysates from ileal longitudinal muscle and myenteric plexus; c) isometric muscle tension with electric field and pharmacological (carbachol) stimulation of ileal segments; and d) intestinal inflammation by levels of tumor necrosis factor α, interleukin(IL)-1β, IL-10 and IL-4. RESULTS: S. boulardii CNCM I-745 improved HSV-1 induced intestinal dysmotility and alteration of intestinal transit observed ten weeks after IG inoculum of the virus. Also, the probiotic yeast ameliorated the structural alterations of the ENS induced by HSV-1 (i.e., reduced peripherin immunoreactivity and expression, increased glial S100β protein immunoreactivity and neuronal nitric oxide synthase level, reduced substance P-positive fibers). Moreover, S. boulardii CNCM I-745 diminished the production of HSV-1 associated pro-inflammatory cytokines in the myenteric plexus and increased levels of anti-inflammatory interleukins. CONCLUSIONS: S. boulardii CNCM I-745 ameliorated gastrointestinal neuromuscular anomalies in a mouse model of gut dysfunctions typically observed with irritable bowel syndrome. PMID: 28732069 [PubMed - in process] View the full article

Google-Here's How Helping Your Brain Can Actually Help Your Gut - ScienceAlert

Jul 22, 2017
Here's How Helping Your Brain Can Actually Help Your Gut ScienceAlert About 20 percent of adults and adolescents suffer from irritable bowel syndrome (IBS), a disorder where abdominal discomfort or pain go hand-in-hand with changes in bowel habits. These could involve chronic diarrhoea and constipation, or a mixture of ... View the full article

Google-Potential Dietary Supplement for Irritable Bowel Syndrome Sufferers - Medical News Bulletin

Jul 21, 2017
Potential Dietary Supplement for Irritable Bowel Syndrome Sufferers Medical News Bulletin Many strategies for treating the symptoms of irritable bowel syndrome (IBS) involve dietary modifications; however, these diets can be restrictive. A recent study formulated low oral nutrition supplement (ONS) beverages with low fermentable oligo-, di ... New Report Examines the Growth of Irritable Bowel Syndrome Drugs Market Forecast to 2025Medgadget (blog) all 2 news articles » View the full article

Google-New Report Examines the Growth of Irritable Bowel Syndrome Drugs Market Forecast to 2025 - Medgadget (blog)

Jul 21, 2017
New Report Examines the Growth of Irritable Bowel Syndrome Drugs Market Forecast to 2025 Medgadget (blog) Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder, a common ailment that affects the colon. Some of the effects of IBS are gas, bloating, pain, constipation, and diarrhea. Long term management is required for IBS as it is a chronic ... View the full article

Pubmed-INTESTINAL MICROBIOTA IN DIGESTIVE DISEASES.

Jul 21, 2017
Related Articles INTESTINAL MICROBIOTA IN DIGESTIVE DISEASES. Arq Gastroenterol. 2017 Jul 06;:0 Authors: Passos MDCF, Moraes-Filho JP Abstract BACKGROUND: In recent years, especially after the development of sophisticated metagenomic studies, research on the intestinal microbiota has increased, radically transforming our knowledge about the microbiome and its association with health maintenance and disease development in humans. Increasing evidence has shown that a permanent alteration in microbiota composition or function (dysbiosis) can alter immune responses, metabolism, intestinal permeability, and digestive motility, thereby promoting a proinflammatory state. Such alterations can mainly impair the host's immune and metabolic functions, thus favoring the onset of diseases such as diabetes, obesity, digestive, neurological, autoimmune, and neoplastic diseases. This comprehensive review is a compilation of the available literature on the formation of the complex intestinal ecosystem and its impact on the incidence of diseases such as obesity, non-alcoholic steatohepatitis, irritable bowel syndrome, inflammatory bowel disease, celiac disease, and digestive neoplasms. CONCLUSION:: Alterations in the composition and function of the gastrointestinal microbiota (dysbiosis) have a direct impact on human health and seem to have an important role in the pathogenesis of several gastrointestinal diseases, whether inflammatory, metabolic, or neoplastic ones. PMID: 28723981 [PubMed - as supplied by publisher] View the full article

Pubmed-Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.

Jul 21, 2017
Related Articles Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):102-107 Authors: Spagnuolo R, Cosco C, Mancina RM, Ruggiero G, Garieri P, Cosco V, Doldo P Abstract OBJECTIVE: To evaluate the efficacy of a mixture of beta-glucan, inositol and digestive enzymes in improving gastrointestinal symptoms in patients affected by inflammatory bowel disease (IBD)-irritable bowel syndrome (IBS). PATIENTS AND METHODS: The study was conducted at the IBD Unit of the University of Catanzaro. Forty-three IBD patients with IBS symptoms were included in the study. IBD diagnosis was performed by clinical, endoscopic, histological and radiological criteria. Patients were in clinical remission and in treatment only with systemical and topical mesalamine. All study participants fulfilled the Rome III criteria for the diagnosis of IBS. The study participants were randomized into 2 groups: group A (n=23) received conventional treatment (systemical and topical mesalamine) plus a mixture of beta-glucan, inositol and digestive enzymes (one tablet after lunch and dinner) for four consecutive weeks; group B (n=20) received only conventional treatment. The prevalence and intensity of gastrointestinal (GI) symptoms were evaluated both at the enrollment (T0) and after four weeks of treatment (T1). RESULTS: Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment. Importantly, an overall improvement in the general well-being has been recorded. Patients who underwent only mesalamine treatment (group B) reported a mild reduction in the evacuative urgency without any other improvements. CONCLUSIONS: We have shown that supplementation with a mixture of beta-glucan, inositol and digestive enzymes reduces bloating, flatulence and abdominal pain, improving the overall clinical condition of IBD-IBS patients. PMID: 28724171 [PubMed - in process] View the full article

Pubmed-New psychological therapies for irritable bowel syndrome: mindfulness, acceptance and commitment therapy (ACT).

Jul 21, 2017
Related Articles New psychological therapies for irritable bowel syndrome: mindfulness, acceptance and commitment therapy (ACT). Rev Esp Enferm Dig. 2017 Jul 14;109: Authors: Sebastián Sánchez B, Gil Roales-Nieto J, Ferreira NB, Gil Luciano B, Sebastián Domingo JJ Abstract The current goal of treatment in irritable bowel syndrome (IBS) focuses primarily on symptom management and attempts to improve quality of life. Several treatments are at the disposal of physicians; lifestyle and dietary management, pharmacological treatments and psychological interventions are the most used and recommended. Psychological treatments have been proposed as viable alternatives or compliments to existing care models. Most forms of psychological therapies studied have been shown to be helpful in reducing symptoms and in improving the psychological component of anxiety/depression and health-related quality of life. According to current NICE/NHS guidelines, physicians should consider referral for psychological treatment in patients who do not respond to pharmacotherapy for a period of 12 months and develop a continuing symptom profile (described as refractory irritable bowel syndrome). Cognitive behavioral therapy (CBT) is the best studied treatment and seems to be the most promising therapeutic approach. However, some studies have challenged the effectiveness of this therapy for irritable bowel syndrome. One study concluded that cognitive behavioral therapy is no more effective than control placebo attention and another study showed that the beneficial effects wane after six months of follow-up. A review of mind/body approaches to irritable bowel syndrome has therefore suggested that alternate strategies targeting mechanisms other than thought content change might be helpful, specifically mindfulness and acceptance-based approaches. In this article we review these new psychological treatment approaches in an attempt to raise awareness of alternative treatments to gastroenterologists that treat this clinical syndrome. PMID: 28724306 [PubMed - as supplied by publisher] View the full article

Pubmed-Enigma of Intestinal Gas in Irritable Bowel Syndrome.

Jul 21, 2017
Related Articles Enigma of Intestinal Gas in Irritable Bowel Syndrome. Am J Gastroenterol. 2017 Jul;112(7):1166-1167 Authors: Uno Y PMID: 28725060 [PubMed - in process] View the full article

Pubmed-Erratum to: the role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis.

Jul 21, 2017
Related Articles Erratum to: the role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis. Parasitol Res. 2017 Jul 18;: Authors: Rostami A, Riahi SM, Haghighi A, Saber V, Armon B, Seyyedtabaei SJ PMID: 28725935 [PubMed - as supplied by publisher] View the full article

Pages